key: cord-0979879-fang0dsc
authors: Rutherford, Matthew A; Scott, Jennifer; Karabayas, Maira; Antonelou, Marilina; Gopaluni, Seerapani; Gray, David; Barrett, Joe; Brix, Silke R; Dhaun, Neeraj; McAdoo, Stephen P; Smith, Rona M; Geddes, Colin; Jayne, David; Luqmani, Raashid; Salama, Alan D; Little, Mark; Basu, Neil
title: Risk factors for severe outcomes in patients with systemic vasculitis & COVID‐19: a bi‐national registry‐based cohort study
date: 2021-03-22
journal: Arthritis Rheumatol
DOI: 10.1002/art.41728
sha: 7ddc330f71ef50aed16c0c71cd13154c0a149c19
doc_id: 979879
cord_uid: fang0dsc

OBJECTIVE: COVID‐19 is a novel infectious disease with a broad spectrum of clinical severity. Patients with systemic vasculitis have an increased risk of serious infections and so may be at risk of severe outcomes following COVID‐19. It is important to establish the risk factors for severe COVID‐19 outcomes in these patients, including the impact of immunosuppressive therapies. METHODS: A multi‐centre cohort was developed through the participation of centres affiliated with national UK and Ireland vasculitis registries. Clinical characteristics and outcomes were described. Logistic regression was used to evaluate associations between potential risk factors and severe COVID‐19 outcome, defined as a requirement for advanced oxygen therapy, invasive ventilation, or death. RESULTS: Sixty‐five cases of patients with systemic vasculitis who developed COVID‐19 were reported (median age 70 years, 49% female) of whom 25 (38%) experienced a severe outcome. Most cases (55/65, 85%) had ANCA‐associated vasculitis (AAV). Almost all patients required hospitalization (59/65, 91%), 7 patients (11%) were admitted to intensive care and 18 patients (28%) died. Background glucocorticoid therapy was associated with severe outcome (adjusted odds ratio [aOR] 3.7 (1.1‐14.9, p=0.047)) as was comorbid respiratory disease (aOR 7.5 (1.9‐38.2, p=0.006)). Vasculitis disease activity and non‐glucocorticoid immunosuppression were not associated with severe outcome. CONCLUSION: In patients with systemic vasculitis, glucocorticoid use at presentation and comorbid respiratory disease were associated with severe outcomes in COVID‐19. These data can inform clinical decision making relating to risk of severe COVID‐19 in this vulnerable patient group.

Coronavirus disease 2019 (COVID-19) is a novel, multi-system infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 causes a broad spectrum of clinical severity (1) , ranging from asymptomatic disease to severe respiratory failure and death. In March 2020 the World Health Organisation characterized COVID-19 as a global pandemic (2) prompting considerable concerns from health care systems globally about their resilience to manage this threat. Critical care service capacity was, and remains, a global priority.

Systemic vasculitis is a rare, multi-system autoimmune disorder. Compared to other rheumatic musculoskeletal diseases, it may result in major organ dysfunction and so is typically managed with more potent immunosuppression and higher doses of glucocorticoids in order to induce and maintain disease remission. While this therapeutic approach successfully manages vasculitis activity, glucocorticoid exposure contributes, in part, to the increased risk of infection in these patients (3, 4) . Thus, although risk factors associated wth poor outcomes from COVID-19 in this population are unknown, there is an assumption that these patients are at high risk.

The RECOVERY trial has demonstrated a benefit from moderate dose glucocorticoids in hospitalized general population patients with COVID-19 requiring supplemental oxygen or mechanical ventilation, but potential harm when used in milder disease (5) . Given these paradoxical effects, it is unknown whether chronic background glucocorticoid exposure makes patients more susceptible to severe COVID-19 infection, or whether it might be protective.

We report the results of a coordinated bi-national effort to identify the predictors of severe outcome in the largest reported cohort of systemic vasculitis patients infected with COVID-19.

This article is protected by copyright. All rights reserved

A registry-based multi-centre cohort was designed to facilitate rapid real-world data capture.

Centres affiliated with the UK and Ireland Vasculitis Registry (UKIVAS; www.ukivas.org/) and the Irish Rare Kidney Disease Registry (RKD; www.tcd.ie/medicine/thkc/research/rare.php) were invited to contribute. UKIVAS covers 89 sites; RKD covers 8 sites across Ireland. Participating centres represent both secondary and tertiary centres across the UK and Ireland resulting in a broad population sampling frame. A vasculitis-focused COVID-19 case report form (CRF) was developed, underpinned by standardized BioPortal ontologies (e.g. SNOMED CT) (6) and interoperable with other emerging datasets such as the COVID-19 Global Rheumatology Alliance (GRA) (7), thereby facilitating future international data linkage as the COVID-19 pandemic progresses. This enables compatibility of these data with the principles of the global GO-FAIR initiative (8) . Additional modules of the UKIVAS and RKD webapps were developed to support data capture.

Patients were eligible for case submission if they had a diagnosis of systemic vasculitis and COVID-19 (laboratory, radiological or clinical). The diagnosis of vasculitis was determined by the local specialist clinician, as per the International Chapel Hill Consensus Nomenclature of Vasculitides (9) . Recruitment commenced on 28 March 2020 and is ongoing. For this analysis, the final case was submitted on 31 July 2020. The population sampling frame consisted of individuals under the clinical care of sites associated with the UKIVAS and RKD registries. At the end of July 2020 there were 795 patients in the RKD registry and approximately 7400 patients in the UKIVAS registry, with 4 patients being enrolled in both. In the UK, the Health Research Authority decision tool determined that ethics approval was not required and the local sponsor confirmed the project as a service evaluation (R&D reference GN20RH165). RKD registry ethics approval was originally granted by the Tallaght University Hospital/St. James's Hospital Joint Research Ethics Committee (ref 2019-08 List 29 (07)). All RKD participants provided informed consent. Additional approvals were not required.

Variables collected included potential predictors of severe outcome. The selection of predictive variables was informed by emerging risk factors for COVID-19 disease severity in other populations (10, 11) . These included age, sex, ethnicity, smoking status, comorbid conditions, immunosuppressive treatment for vasculitis and vasculitis disease activity. Within comorbid

This article is protected by copyright. All rights reserved conditions, respiratory disease refers to non-vasculitis related lower respiratory tract disease, though it is possible that some patients had coexistent vasculitis related respiratory disease.

Intravenous immunosuppressive therapy was considered to be 'current' if the assessing clinician determined that the therapy was likely to be exerting a biological effect at the time of COVID-19 diagnosis, specific definitions were not provided. Vasculitis disease activity was determined according to global clinician assessment. Outcome data collected included complications, such as acute kidney injury (AKI), respiratory failure and vasopressor requirement, and death. To enable interoperability, the same standardized 1-8 graded outcome as the COVID-19 Global Rheumatology Alliance (GRA) was used (Supplementary Table 1 Reporting clinicians were asked to indicate which of these variables contributed to diagnosis.

Continuous variables were described as median (IQR). Categorical variables were described as number and percentage (%). Association between various explanatory variables and the odds of severe outcome was determined. Unadjusted and age/sex adjusted logistic regression models were individually calculated for each explanatory variable and reported as odds ratios (OR), pvalues and 95% confidence intervals (95% CIs). The adjusted odds ratios (aOR) for age and sex were derived from a single logistic regression model which included age and sex only. Where a potential interaction could account for a positive finding, logistic regression modeling incorporating the explanatory and interacting variables was used. Sensitivity analyses were performed where any effects may have been different in an important subgroup. Missing data were stated in the relevant tables. Statistical significance was set at 5%. R (version 4.0.2) was used for data analysis with packages including tidyverse and finalfit.

In total, 65 patients with an established diagnosis of systemic vasculitis who developed COVID-19 were registered. Fifty-eight patients were submitted to UKIVAS and 7 were submitted to RKD, with no duplicate submissions. (Table 1) Median age was 70 years (IQR 55-76) and 49% were female. The majority (55/65, 85%) had anti- Forty-seven patients (72%) were diagnosed by PCR testing, 3 (5%) did not have PCR confirmed disease but had radiological evidence, 3 (5%) were diagnosed by clinical presentation only. Data on diagnostic testing were unknown/missing for 12 patients (18%). The characteristics of those diagnosed by PCR testing were broadly similar to the full cohort (data not shown).

Most patients were receiving background glucocorticoids (45/65, 69%) at the time of COVID-19 diagnosis. Nineteen (29%) were receiving the equivalent of 5 mg prednisone or less, 26/65 (40%) were receiving more than 5 mg. For those on background glucocorticoid, the median dose was the equivalent of 7.5 mg prednisone daily (IQR 5-25 mg). Twenty-two (34%) and 10 (15%) were recently treated with rituximab and cyclophosphamide, respectively.

The most common symptoms were dyspnoea (41/65, 63%), fever (38/65, 58%) and cough (37/65, 57%). Hemoptysis occurred in 3 individuals (5%) and epistaxis occurred in 3 individuals (5%) -of these, one patient had both epistaxis and haemoptysis. Of note, some of these patients had ongoing disease activity prior to COVID-19 diagnosis.

This article is protected by copyright. All rights reserved Respiratory failure was the most commonly reported complication (35/65, 54%), followed by AKI (12/65, 18%) and secondary infection (10/65, 15%).

Almost all patients required hospitalization (59/65, 91%); 7/65 (11%) were admitted to an intensive care unit (ICU) and 18/65 (28%) died. Median length of hospital stay for discharged patients was 11 days (IQR 5-27). A severe outcome was experienced by 25/65 (38%). (Table 3) Patients with comorbid respiratory disease were more likely to suffer a severe outcome than those without (aOR 7.5, 95% CI 1.9-38.2, p=0.006) as were those prescribed glucocorticoids (aOR 3.7, 95% CI 1.1-14.9, p=0.047). Glucocorticoid exposure remained a poor prognostic indicator even after adjusting for vasculitis disease activity (data not shown). A sensitivity analysis including only those with confirmed PCR diagnosis (n = 47) was performed which demonstrated effect sizes consistent with these findings, this was statistically significant for comorbid respiratory disease but not for glucocorticoid exposure (data not shown). A sensitivity analysis was also performed for individuals with AAV (n = 55) with a similar result. There was insufficient power to assess the association between glucocorticoid dose and poor outcome. Similarly there was insufficient power to assess for differences between common non-glucocorticoid immunosuppressive agents. Associations were not demonstrated for any demographics, other comorbid conditions, vasculitis diagnosis, vasculitis disease activity or non-glucocorticoid immunosuppressant medication.

This article is protected by copyright. All rights reserved

This multi-centre study reports the largest cohort of patients with systemic vasculitis developing COVID-19 to date. It identifies comorbid respiratory disease and background glucocorticoid therapy as significant predictors of a severe outcome, as defined by need for advanced oxygen therapy or invasive ventilation, or death. Routinely used non-glucocorticoid immunosuppressants, such as rituximab and cyclophosphamide were not associated with a severe outcome and neither was vasculitis disease activity.

Glucocorticoids have pleotropic immunological effects and are generally considered risk factors for infections (12) . Glucocorticoids at high dose have been associated with prolonged viral shedding, with a similar effect being observed in other coronaviruses (13, 14) . That glucocorticoids associate with worse COVID-19 disease is consistent with findings from across the rheumatic autoimmune spectrum, as reported by COVID-19 GRA (10). Our point estimate for the association of any glucocorticoid dose with severe outcome (OR 3.66; 95% CI 1.09-14.9) was comparable to the COVID-19 GRA study's evaluation of steroids at or above the equivalent of 10 mg prednisolone per day (OR 2.05; 1.06 to 3.96). The confidence interval for this finding is relatively wide and therefore it remains to be determined if there is a dose threshold at which risk commenses. This association between glucocorticoids and severe outcome may appear to conflict with findings from the RECOVERY trial. This trial found that low-dose dexamethasone had a substantial survival benefit in individuals hospitalised with COVID-19. However, the groups that benefited in RECOVERY were those requiring supplemental oxygen with the greatest benefit being derived in those requiring mechanical ventilation. In fact, the point estimate for those not requiring oxygen suggested that glucorticoids could be associated with increased mortality, though this was not a statistically significant finding (5) . Therefore, prior to requiring oxygen, it may be that glucorticoids are deleterious, as observed in this and other studies of autoimmune disease (15) . Our finding that co-morbid respiratory disease (most commonly chronic obstructive pulmonary disease, asthma and interstitial lung disease) was associated with severe disease outcomes was consistent with a recent general population meta-analysis (16) . Enhanced respiratory tract ACE2 expression, the principal binding site for COVID-19 cell entry, among some patients with chronic lung disease is a possible explanation for this association (10) .

Consistent with the COVID-19 GRA report, we did not find an association with adverse disease outcomes for other immunosuppressive agents (17) . This is reassuring since current guidance emphasises the importance of maintaining immunosuppression therapy among uninfected patients due to concerns of destabilising disease control (18) .

This article is protected by copyright. All rights reserved This cohort represents a severely affected group, as reflected by the very high proportion of hospitalisation (91%). The mortality rate of 28% is similar to that reported in the largest UK study of hospitalised patients carried out by the ISARIC WHO Clinical Characterisation Protocol UK group in which 26% died (18) . Age, sex and symptom distribution were also broadly similar to the ISARIC WHO report. The most common symptoms, in that cohort and ours, were those which have been most prominent in the case definition: breathlessness, fever and cough. Both active pulmonary vasculitis and COVID-19 are recognised causes of haemoptysis (18, 19) . In the ISARIC WHO UK group 3.5% had this symptom, 3 (4.8%) patients experienced this symptom in our cohort. None were thought to have diffuse alveolar haemorrhage, as judged by the responding clinician. Differentiating COVID-19 from active pulmonary vasculitis remains a challenge and indeed these presentations may coexist. Ensuring these diagnoses are considered where a patient with vasculitis presents with haemoptysis remains of high importance.

A large proportion (49%) of patients had concurrent active vasculitis. Of these a considerable proportion was suspected to have acquired COVID-19 from a healthcare setting. Notably, the onset of vasculitis disease activity preceded COVID-19 infection in almost all cases. However, it is unknown if COVID-19 may trigger vasculitis activity in the longer term. The emergence of paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS), a condition bearing strong similarities to Kawasaki disease, is a potential example of SARS-CoV-2 triggering autoimmune vasculitis, though the pathogenesis is currently not understood (20) . Our study did not find evidence of vasculitis being triggered in the short-term. Longitudinal studies will seek to address this question. The prevalence of active disease in this cohort is higher than expected -previous cross-sectional UK studies have reported disease activity prevalence at approximately 20% (21). Although disease activity was not associated with worse outcome, it may be that patients with unstable disease are more vulnerable to contracting COVID-19. Physician or patient-led reduction in immunosuppressive treatment, in a bid to limit the impact of COVID-19, is another potential reason accounting for a high proportion of disease activity. Due to study design, our data are limited in the extent to which they can inform this question.

Ascertainment bias is likely to have affected this study. Given that most patients were hospitalized, it is likely that patients with milder disease were not identified. The number of PCR diagnosed patients in our study as a proportion of the combined UKIVAS and RKD populations was similar to the proportion of UK cases relative to the UK population for a comparable time period (22). However due to study design, it is not possible to derive incidence rates and patients Accepted Article with vasculitis may have been more likely to have contracted COVID-19 due to risk factors such as immunosuppressive therapy and need to attend healthcare facilities, therefore ascertainment bias remains possible. There was a high preponderance of small vessel vasculitis (SVV) in this study compared to giant cell arteritis (GCA). Although more common, individuals with GCA are typically older and may have adopted stricter self-isolation restrictions (as per national guidance).

In addition, SVV may have predominated due to a disproportionate number of renal units compared to rheumatology centres represented in UKIVAS. Due to a large majority of patient in this study having SVV, the extent to which the findings of this study can be generalised to other vasculitides is limited. Other limitations of this study include relative lack of power. As a result, our analyses may not detect some clinically significant effects and conversely the risk of spurious findings are higher. Similarly, due to the limited number of events, our ability to control for multiple potential confounding factors was limited. Due to the heterogeneous immunobiology, phenotypes and management approaches of systemic vasculitis it is possible that individual disorders may incur different risks, due to insufficient power we were limited in the extent to which this could be examined.

This study is the first to describe a cohort of vasculitis patients with COVID- 19 Together with reports of other cohorts exposed to immunosuppressant medication, these data could inform future public health guidance for individuals with autoimmune disease. These data 

This article is protected by copyright. All rights reserved 

This article is protected by copyright. All rights reserved 

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 -11

Immunosuppressive and glucocorticoid therapy for the treatment of ANCAasssociated vasculitis

Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

The National Center for Biomedical Ontology

The COVID-19 Global Rheumatology Alliance. The COVID-19 Global Rheumatology Alliance

The FAIR Guiding Principles for scientific data management and stewardship

revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides

Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry

OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients

Immune regulation by glucocorticoids

Dexamethasone in the management of covid -19

High-dose but not low-dose corticosteroids potentially delay viral shedding of patients with COVID-19

Underlying respiratory diseases, specifically COPD, and smoking are associated with severe COVID-19 outcomes: A systematic review and metaanalysis

Cigarette Smoke Exposure and Inflammatory Signaling Increase the Expression of the SARS-CoV-2 Receptor ACE2 in the Respiratory Tract

EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

ANCA-associated vasculitis

Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking

The authors wish to thank the following individuals who contributed data for this project: Jocelyn 

This article is protected by copyright. All rights reserved

This article is protected by copyright. All rights reserved